The effects of serum lipids on the in vitro activity of lumefantrine and atovaquone against Plasmodium falciparum

被引:6
|
作者
Chotivanich, Kesinee [1 ]
Mungthin, Mathirut [2 ]
Ruengweerayuth, Ronnatrai [3 ]
Udomsangpetch, Rachanee [4 ]
Dondorp, Arjen M. [1 ]
Singhasivanon, Pratap [1 ]
Pukrittayakamee, Sasithon [1 ]
White, Nicholas J. [1 ,5 ]
机构
[1] Mahidol Univ, Fac Trop Med, MORU, Bangkok 10400, Thailand
[2] Phramongkutklao Coll Med, Dept Parasitol, Bangkok 10400, Thailand
[3] Mae Sot Hosp, Tak, Thailand
[4] Mahidol Univ, Fac Sci, Dept Pathobiol, Bangkok 10400, Thailand
[5] Univ Oxford, Churchill Hosp, Ctr Trop Med, Oxford, England
来源
MALARIA JOURNAL | 2012年 / 11卷
基金
英国惠康基金;
关键词
Malaria; Anti-malarial drugs; In vitro-susceptibility; ANTIMALARIAL-DRUG RESISTANCE; ARTESUNATE-MEFLOQUINE; VIVAX MALARIA; CHLOROQUINE; BENFLUMETOL; BIOAVAILABILITY; HALOFANTRINE;
D O I
10.1186/1475-2875-11-177
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Lumefantrine and atovaquone are highly lipophilic anti-malarial drugs. As a consequence absorption is increased when the drugs are taken together with a fatty meal, but the free fraction of active drug decreases in the presence of triglyceride-rich plasma lipoproteins. In this study, the consequences of lipidaemia on anti-malarial drug efficacy were assessed in vitro. Methods: Serum was obtained from non-immune volunteers under fasting conditions and after ingestion of a high fat meal and used in standard Plasmodium falciparum in-vitro susceptibility assays. Anti-malarial drugs, including lumefantrine, atovaquone and chloroquine in five-fold dilutions (range 0.05 ng/ml - 1 ug/mL) were diluted in culture medium supplemented with fasting or post-prandial 10% donor serum. The in-vitro drug susceptibility of parasite isolates was determined using the H-3-hypoxanthine uptake inhibition method and expressed as the concentration which gave 50% inhibition of hypoxanthine uptake (IC50). Results: Doubling plasma triglyceride concentrations (from 160 mg/dL to 320 mg/dL), resulted in an approximate doubling of the IC50 for lumefantrine (191 ng/mL to 465 ng/mL, P < 0.01) and a 20-fold increase in the IC50 for atovaquone (0.5 ng/mL to 12 ng/ml; P < 0.01). In contrast, susceptibility to the hydrophilic anti-malarial chloroquine did not change in relation to triglyceride content of the medium. Conclusions: Lipidaemia reduces the anti-malarial activity of lipophilic anti-malarial drugs. This is an important confounder in laboratory in vitro testing and it could have therapeutic relevance.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] The effects of serum lipids on the in vitro activity of lumefantrine and atovaquone against Plasmodium falciparum
    Kesinee Chotivanich
    Mathirut Mungthin
    Ronnatrai Ruengweerayuth
    Rachanee Udomsangpetch
    Arjen M Dondorp
    Pratap Singhasivanon
    Sasithon Pukrittayakamee
    Nicholas J White
    Malaria Journal, 11
  • [2] Potentiation of the antimalarial activity of atovaquone by doxycycline against Plasmodium falciparum in vitro
    Yeo, AET
    Edstein, MD
    Shanks, GD
    Rieckmann, KH
    PARASITOLOGY RESEARCH, 1997, 83 (05) : 489 - 491
  • [3] Potentiation of the antimalarial activity of atovaquone by doxycycline against Plasmodium falciparum in vitro
    Anthony E. T. Yeo
    Michael D. Edstein
    G. Dennis Shanks
    Karl H. Rieckmann
    Parasitology Research, 1997, 83 : 489 - 491
  • [4] Prophylactic activity of atovaquone against Plasmodium falciparum in humans
    Shapiro, TA
    Ranasinha, CD
    Kumar, N
    Barditch-Crovo, P
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1999, 60 (05): : 831 - 836
  • [5] Biguanide-atovaquone synergy against Plasmodium falciparum in vitro
    Jones, K
    Ward, SA
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) : 2700 - 2703
  • [6] IN-VITRO ACTIVITY OF ATOVAQUONE AGAINST THE AFRICAN ISOLATES AND CLONES OF PLASMODIUM-FALCIPARUM
    BASCO, LK
    RAMILIARISOA, O
    LEBRAS, J
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1995, 53 (04): : 388 - 391
  • [7] In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum
    Dormoi, Jerome
    Savini, Helene
    Amalvict, Remy
    Baret, Eric
    Pradines, Bruno
    MALARIA JOURNAL, 2014, 13
  • [8] In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum
    Jérome Dormoi
    Hélène Savini
    Rémy Amalvict
    Eric Baret
    Bruno Pradines
    Malaria Journal, 13
  • [9] In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon
    Basco, LK
    Bickii, J
    Ringwald, P
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) : 2347 - 2351
  • [10] Alternative oxidase inhibitors potentiate the activity of atovaquone against Plasmodium falciparum
    Murphy, AD
    Lang-Unnasch, N
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (03) : 651 - 654